Ozen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ozen

What is Ozen? An Overview of Identity and Type

The medicine Ozen is a preparation containing the active substance Cetirizine Dihydrochloride, a well-established agent used for managing symptoms associated with allergic conditions. It is classified as a modern second-generation antihistamine, a type of drug designed for targeted systemic relief.

Property Description
Active Ingredient Cetirizine Dihydrochloride
Form Tablet, Oral Solution, Syrup
Pharmacological Class Second-Generation Antihistamine
Common Use Symptomatic relief of allergic conditions
Origin Synthetic, metabolite of Hydroxyzine

Ozen's Identity: Active Ingredient, Origin, and Form

Ozen, which delivers the chemical compound Cetirizine Dihydrochloride, is a synthetic compound derived from the metabolism of Hydroxyzine. This substance is recognized as a carboxy-metabolite of its parent compound. The active ingredient is a single component dedicated to providing antiallergic effects. For systemic administration, Ozen is available in multiple dosage forms, including the standard film-coated tablet and liquid preparations like oral solution and syrup, which allow flexibility in intake, particularly for pediatric use.

Cetirizine Dihydrochloride is used in both adults and children as a compound for allergy management, maintaining a recognized profile for these applications.


Classification and General Purpose of Cetirizine Dihydrochloride

Ozen is classified as a selective peripheral H1-receptor blocker, placing it firmly in the category of second-generation antihistamines. This distinction is key: second-generation agents are highly selective for peripheral receptors and have minimal ability to cross the blood-brain barrier compared to older antihistamines. This characteristic is intended to target allergic symptoms while reducing the likelihood of sedative effects.

Consequently, the drug's general therapeutic purpose is to provide relief by blocking the activity of histamine, the natural substance that triggers allergic responses. Cetirizine Dihydrochloride is utilized for addressing the physical manifestations of immune hypersensitivity reactions, such as symptoms related to seasonal allergies, establishing its role in managing these episodes.

What side effects are possible with Ozen?

Officially Documented Adverse Reactions and Safety Profile

The safety profile of Ozen (Cetirizine Dihydrochloride) is established through official regulatory documents, which classify adverse reactions according to their frequency and the physiological system affected. The most frequently documented effects involve the nervous system and gastrointestinal tract.

Classification of Side Effects by Frequency

Adverse reactions are formally grouped into categories based on reporting incidence:

Frequency Examples of Listed Adverse Reactions
Common (Up to 1 in 10) Somnolence, dizziness, headache, fatigue, dry mouth, nausea, diarrhea.
Uncommon (Up to 1 in 100) Paresthesia, abdominal pain, pruritus, rash, agitation, malaise.
Rare (Up to 1 in 1,000) Hypersensitivity reactions, tachycardia, convulsions, abnormal liver function, weight gain, aggression.
Very Rare (Up to 1 in 10,000) Thrombocytopenia, syncope, angioedema, fixed drug eruption.

Serious adverse reactions, though classified in the rare or very rare frequency tiers, include anaphylactic shock and documented cases of hepatic function abnormality.

Population-Specific Safety Considerations

The medicine is contraindicated in individuals with severe renal impairment, defined as a creatinine clearance less than 10 mL/ min, as the substance is primarily excreted by the kidneys. Caution is also advised when Ozen is used in older adults, due to the potential for age-related decrease in renal function. Additionally, concomitant use with alcohol or other Central Nervous System (CNS) depressants may cause additive reduction in alertness and impairment of performance.

Specific patterns noted in regulatory documents include somnolence often being reported early in treatment, and the potential for rebound pruritus upon discontinuation, particularly following long-term use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Ozen (Cetirizine Dihydrochloride) describes documented overdose presentations and the required emergency actions.

Documented Manifestations and Severe Outcomes

Overdose is primarily characterized by a spectrum of Central Nervous System (CNS) effects. The most commonly documented sign is pronounced somnolence or drowsiness, but the spectrum also includes agitation, restlessness, confusion, dizziness, and headache. Documented systemic manifestations include tachycardia (rapid heart rate), diarrhoea, and difficulty with urination (micturition difficulty). Overdose in the paediatric population may initially present with restlessness and irritability prior to sedation. Regulatory sources note the potential for rare, serious outcomes, including convulsions, syncope (fainting), and abnormal hepatic function (elevated enzymes and bilirubin).

Emergency Action and Management

Due to the potential for serious effects, official guidance mandates that individuals seek professional assistance immediately or consult a doctor immediately if overdose is suspected or confirmed. There is no known specific antidote for Ozen overdose. Treatment is strictly limited to symptomatic and supportive measures. Gastric lavage may be considered by a healthcare professional if performed shortly after ingestion.

Therapeutic Uses of Ozen

Main Uses and Benefits of Ozen

Ozen (ozanimod) is a sphingosine 1-phosphate (S1P) receptor modulator primarily used in the management of specific chronic inflammatory conditions. It works by retaining certain white blood cells in the lymph nodes, preventing them from entering the central nervous system or the gastrointestinal tract where they could cause damage.

Relapsing Forms of Multiple Sclerosis

Ozen is used for the treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The primary goals of treatment in these conditions include:

  • Reduction of Relapse Rates: Helping to decrease the frequency of clinical flare-ups or new symptoms.
  • Delaying Physical Disability: Slowing the progression of physical impairment over time.
  • Reduction of Brain Lesions: Decreasing the number of active areas of inflammation and new or enlarging permanent damage in the brain as seen on magnetic resonance imaging (MRI).

Ulcerative Colitis

Ozen is also indicated for the treatment of adults with moderately to severely active ulcerative colitis, a chronic inflammatory bowel disease. In this context, the medication is used to manage symptoms and improve the internal state of the colon.

  • Clinical Remission: Achieving a state where the clinical symptoms of the disease, such as rectal bleeding and stool frequency, are significantly reduced or absent.
  • Endoscopic Improvement: Promoting the healing of the intestinal lining (mucosa), which can be observed during endoscopic examinations.
  • Clinical Response: Providing an early and sustained reduction in disease activity for patients who have not responded adequately to other treatments.

Mechanism of Action and Systemic Benefits

By targeting S1P receptors (specifically types 1 and 5), Ozen provides a targeted approach to immunomodulation. Unlike broad immunosuppressants, its mechanism focuses on the migration of lymphocytes. This targeted action helps manage the underlying inflammatory processes characteristic of MS and ulcerative colitis, aiming for long-term stabilization of these chronic conditions.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Population Eligibility and Restrictions

Regulatory criteria define specific groups for whom the use of Ozen is either permitted, restricted, or strictly prohibited.

Contraindications (Must Not Use) Ozen is contraindicated in patients with a known hypersensitivity to Cetirizine Dihydrochloride, its excipients, Hydroxyzine, or any piperazine derivatives. Use is also strictly prohibited in patients with severe renal impairment or End-Stage Renal Disease (creatinine clearance < 10 mL/min).


Age-Group Eligibility The medicine is approved for adults and adolescents ge 12 years and, for certain formulations, children ge 6 months. However, the tablet formulation is not recommended for children under six years of age, as it does not allow for necessary dose adaptation.


Conditional and Restricted Use Patients with mild or moderate renal impairment require individualized dose adjustment and consultation. Ozen is not recommended for women who are breastfeeding due to its excretion into breast milk. Use during pregnancy is permitted only if clearly needed. Caution is also specifically advised for use in patients who are epileptic or otherwise at risk of convulsions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines clinically significant medicinal product interactions for rivaroxaban, based on authoritative regulatory documentation.

Pharmacokinetic Interaction Domains

Rivaroxaban's metabolism is dependent on the Cytochrome P450 3A (CYP3A) pathway and the efflux transporter P-glycoprotein (P-gp).

  • Combined P-gp and Strong CYP3A Inhibitors: Concomitant use with drugs that are both strong inhibitors of P-gp and CYP3A (e.g., certain azole antifungals) significantly increases rivaroxaban exposure. This combination is typically advised to be avoided due to the heightened risk of bleeding.
  • Combined P-gp and Strong CYP3A Inducers: Drugs that strongly induce both P-gp and CYP3A (e.g., Rifampin) significantly decrease rivaroxaban concentration. This combination is generally avoided as the decreased exposure may increase the risk of thromboembolic events.

Pharmacodynamic Interaction Domains

Interactions that affect the body’s ability to form blood clots can compound the risk associated with rivaroxaban.

  • Other Anticoagulants and Antiplatelet Agents: The co-administration of rivaroxaban with other anticoagulants (e.g., Warfarin, Heparins) is officially restricted and is to be avoided unless a temporary transition period necessitates overlapping use. Concomitant use with antiplatelet agents (e.g., aspirin) further increases the risk of bleeding and requires caution.
  • NSAIDs, SSRIs, and SNRIs: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Selective Serotonin/Serotonin-Norepinephrine Reuptake Inhibitors (SSRIs/SNRIs) independently affect hemostasis. Their co-administration with rivaroxaban may increase the overall risk of bleeding and requires careful consideration.

Mechanism of Action

Mechanism of Action: How Ozenoxacin Works

Dual Disruption of Bacterial DNA Management

Ozenoxacin functions by targeting two essential bacterial enzymes: DNA gyrase (Topoisomerase II) and Topoisomerase IV. The molecule interacts with these enzymes and acts as an inhibitor, binding to the enzyme-DNA complex. This stabilizes the cleaved state of the bacterial DNA strands. The effect is the halting of crucial processes involving genetic replication and chromosome separation, which are fundamental requirements for bacterial cellular function.

Bactericidal Physiological Consequence

This dual enzymatic inhibition initiates a rapid mechanistic cascade within the bacterial cell. The block on re-ligation and separation leads directly to the accumulation of critical DNA strand breaks and physical barriers that prevent cell division. The cellular consequence is a swift and decisive bactericidal action, resulting in the death of the targeted bacterial population, which constitutes the physiological modulation produced by the drug.

Dosage and Administration Information

How to use Ozen

Ozen (Cetirizine Dihydrochloride) is administered following specific, fixed dosage rules. The primary administration method is oral via tablet, oral solution, or syrup, with an intravenous (IV) route for use in acute clinical settings.

Administration Protocol

Instruction Detail
Dosing Schedule (Adults) 10 mg administered as a single dose once daily, or 5 mg once daily for less severe symptoms. The maximum dose is 10 mg per 24 hours.
Timing in Relation to Meals May be taken with or without food, as food intake does not significantly affect the extent of the drug’s absorption.
Age-Group Administration Dose is reduced to 5 mg once daily for older adults with compromised renal function. Pediatric dosing is tiered by age, with children 6 years and older receiving up to 10 mg once daily.
Population-Specific Adjustment For adult patients with moderate to severe renal impairment, the dose is typically reduced to 5 mg once daily due to the drug’s renal elimination.
Missed-Dose Rule If a scheduled dose is forgotten, the instruction is to skip the missed dose and resume the normal schedule; do not take a double dose.

Procedural Context

Oral administration requires the patient to take the medicine once daily, maintaining the fixed schedule until the end of the treatment plan. The standard tablet may be divided into two equal 5 mg doses if required by the prescribed regimen. For acute use, the 10 mg IV injection is administered slowly over a period of one to two minutes within a clinical environment. The medication is used as a fixed-frequency treatment with a defined maximum limit, requiring dose adjustments for patients with reduced kidney function.

Recent Clinical Evidence

Ozen: Recent Clinical Evidence

Mechanism of Action and Core Research

This section summarizes the results of research that has evaluated patient outcomes in managing pain associated with conditions studied with Ozen (formerly Drug A).

  • Mechanism Research
    • Research has explored the mechanism of action of Ozen, focusing on specific pain receptors. Studies investigated whether this mechanism was associated with a reduction in pain severity.
    • Research has investigated the analgesic properties of Ozen in clinical trials involving various populations.
    • Several studies investigated whether combining Ozen with non-pharmacological treatments was associated with a reduction in overall pain burden.

Dose and Administration Variables

Studies have evaluated how different dose strengths and methods of administration influence reported outcomes.

  • Formulation Comparisons
    • Research evaluated whether the higher-dose formulation led to a shorter time to reported pain relief compared to the standard dose.
    • Research investigated whether taking Ozen with food was associated with changes in absorption, a factor that can influence systemic exposure.
    • Studies examined whether discontinuation of Ozen was followed by reports of temporary rebound pain, an outcome often assessed in pain relief trials.

Subgroup Analysis and Comparative Data

Studies have examined the effects of Ozen in specific patient groups and in comparison with other treatments available for similar conditions.

  • Specific Populations
    • Studies evaluated the pharmacokinetics and tolerability of Ozen in individuals with mild kidney impairment and in those with severe liver disease to understand how organ function affects the drug's processing.
    • Comparative studies examined whether Ozen demonstrated differences in outcomes for mobility compared to older treatments in clinical trial settings.

Key Studies & References

  1. Comparative Effectiveness of Ozen vs. Traditional Analgesics on Physical Function and Mobility: An Active-Controlled Trial
  2. Ozen Clinical Practice Guideline for Neuropathic Pain

Frequently Asked Questions (FAQ)

Common questions about Ozen (FAQ)


Q: How quickly does Ozen start to work?

Official information indicates that the effects of the active ingredient typically begin relatively quickly, often within thirty minutes to one hour after taking the oral dose. This is based on the typical time it takes for the substance to become available in the body after administration.

Q: Do I need to avoid any specific foods while taking Ozen?

Regulatory documents state that food intake does not significantly affect how much of the medicine is absorbed into the body. Therefore, the medication may be taken with or without food. No specific food or dietary restrictions are generally noted in major regulatory labels.

Q: Is it common to feel tired after starting Ozen?

Official documents classify somnolence, which is the medical term for drowsiness or tiredness, as a Common side effect, meaning it can affect up to 1 in 10 patients. It is also specifically noted in some official documents that this effect is often reported early in the course of treatment.

Q: What kind of studies have been done on Ozen?

Studies conducted on Ozen include controlled clinical trials, where its properties are explored, and comparative studies against older treatments. These research efforts are used to explore the medicine's safety profile and documented effects in various populations.

Q: What are the long-term safety data for Ozen?

Long-term safety is continuously monitored through post-marketing reports that collect data once the drug is widely available. These reports have noted that the potential for a specific effect, such as new-onset severe itching (pruritus) upon stopping the medicine, may occur, particularly after use spanning several months or years.

Q: Can I stop taking Ozen suddenly?

Official documents describe that stopping the medicine, especially after long-term use, has been associated with reports of temporary rebound itching (pruritus). The official documentation emphasizes the importance of discussing any plans regarding discontinuation with a healthcare professional.

Q: What is Ozen used for besides the main condition?

According to official regulatory indications, Ozen is approved to provide relief from symptoms associated with both seasonal and perennial allergic rhinitis (commonly known as hay fever). It is also used to manage symptoms related to chronic idiopathic urticaria (chronic hives).

Q: Can Ozen cause weight gain or loss?

Weight gain is listed as a Rare side effect in official regulatory documents. Post-marketing surveillance has also mentioned reports of 'increased appetite' but the specific frequency of this effect is not known. Weight loss is not typically noted as an associated side effect.

Q: Does Ozen interact with common pain relievers?

Official information indicates that Ozen is not known to have clinically significant interactions with certain non-opioid pain relievers, such as acetaminophen. Official information notes that co-administration of NSAIDs may require consideration due to potential additive effects on bleeding risk.

Q: Why is Ozen prescribed for different conditions?

Ozen is approved to manage symptoms associated with both seasonal and perennial allergic conditions, specifically chronic hives (urticaria) and allergic rhinitis (hay fever). Its properties allow it to address the undesirable physical manifestations of immune hypersensitivity reactions common to these conditions.

Q: How often is Ozen typically taken?

The medicine is generally administered as a single dose once every 24 hours. The official instructions for administration outline the use of a fixed daily schedule.

Q: What should I do if a side effect doesn't go away?

Official patient information advises contacting a healthcare provider if symptoms of common side effects, such as drowsiness or dry mouth, are severe or persist over time. This action is consistent with patient safety guidance provided in official documents.

Q: When was Ozen first approved by the FDA or a similar agency?

The active ingredient in Ozen has a long history of regulatory review. It was first approved for prescription use in the United States in 1995. The substance was later approved by the FDA for nonprescription (over-the-counter) use in 2007.

Q: Does Ozen make you feel 'drugged' or foggy?

Official product information documents side effects that relate to mental status, including somnolence (drowsiness), dizziness, and fatigue. These effects are related to reduced mental alertness and may be the way a person describes feeling mentally foggy.

Q: Can Ozen affect my blood pressure?

The active substance in Ozen is not known to raise blood pressure when taken on its own. However, official information clarifies that certain combination products that include a decongestant alongside Ozen can potentially affect blood pressure.

Q: Are there any common interactions with over-the-counter medications?

No clinically significant drug interactions have been found with the low dose of theophylline or certain antibiotics. Official guidance generally advises exercising caution when taking Ozen alongside any other medications that cause central nervous system (CNS) depression, as this could increase drowsiness.

Q: Is Ozen safe for children and teenagers?

Ozen is approved with specific, tiered dosing instructions for use in children as young as six months for certain liquid formulations. However, the standard tablet formulation is not recommended for children under six years of age.

Q: Do I need to take Ozen with food, or can I take it on an empty stomach?

Official administration instructions state clearly that the medicine may be taken with or without food. Food intake does not significantly change the way the medicine is absorbed.

Q: What is the evidence for Ozen's effectiveness in real-world patients?

While the drug's properties are established through controlled clinical trials, regulatory agencies continue to monitor post-marketing data and adverse event reports. This surveillance provides safety data for the drug's use in a broader and more diverse patient population outside of the controlled study environment.

Q: Can Ozen cause allergic reactions?

The medicine can cause hypersensitivity reactions, which are allergic reactions. It is strictly contraindicated in patients with a known allergy to the active substance, and rare cases of a severe systemic allergic reaction known as anaphylactic shock have been documented.

Q: What happens if I accidentally take two doses of Ozen close together?

If more than the recommended dose is taken, official patient information advises immediately seeking medical help or contacting a poison control center. Symptoms of taking too much may include restlessness, confusion, or extreme drowsiness.

Q: Are there specific tests I need before starting Ozen?

Patients who have known or suspected kidney or liver disease are advised to consult a healthcare professional. In these situations, a healthcare provider may perform an evaluation, and a dosage adjustment is typically required based on the individual's organ function.

Q: How does Ozen affect driving or operating machinery?

Official documentation notes that caution is required when driving a car or operating potentially dangerous machinery. This is because the medicine can cause side effects like drowsiness and impaired mental alertness.

Q: Can Ozen be crushed or cut in half?

The standard tablet formulation can be physically divided into two equal halves. This allows patients to achieve a prescribed 5 mg dose if the lower-strength tablet is not available.

Q: What is the difference between Ozen and its generic equivalent?

Regulatory guidance confirms that a generic equivalent contains the same active substance (Cetirizine Dihydrochloride) as the brand-name drug. Generics are required to be bioequivalent, meaning they perform identically and achieve the same concentration in the body as the brand-name product.

Q: Can Ozen interact with herbal products like St. John's Wort?

Official patient information generally advises disclosing all prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products currently being taken. This disclosure allows for comprehensive safety review.

Q: What should I tell my doctor before starting Ozen?

Official guidance highlights the importance of disclosing a complete medical history, including any past or present kidney or liver disease. Patients should also disclose current use of any other tranquilizers or sedatives, and whether they are pregnant, plan to become pregnant, or are breastfeeding.

Q: Is it normal to have mild headaches when first taking Ozen?

Headache is listed as a Common side effect, meaning it is one of the more frequently observed effects and may occur in up to 1 in 10 patients. Therefore, experiencing a mild headache is noted as a possibility in official documentation.

How should Ozen be stored and disposed of?

Ozen (Cetirizine Dihydrochloride) must be stored and disposed of based strictly on official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

Storage Parameter Regulatory Requirement
Temperature Store at controlled room temperature (20 C–25 C), protected from excessive heat. Liquid forms should generally be stored below 30 C and must not be frozen.
Protection Keep in the original container with the lid tightly closed, protected from moisture and light.
Child Safety Mandatory to keep Ozen out of the reach and sight of children.

Official Disposal Instructions

Any unused or expired Ozen must be disposed of according to local regulations and pharmaceutical waste programs. Do not dispose of this medicine via household waste or wastewater (e.g., flushing down the toilet) unless specifically advised by a pharmacist or collection program, as this may be required to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ozen found in:

A-Z Index: